paricalcitol (Zemplar)

01/01/2014 - "In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. "
01/01/2017 - "Paricalcitol, the 19 nor-1,25(OH)2D2 analogue was shown to be effective and safe in the treatment of secondary hyperparathyroidism (SHPT) in adults almost two decades ago. "
01/01/2011 - "Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin."
01/01/2013 - "Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis. "
12/01/2005 - "In three double-blind, randomized, placebo-controlled studies to evaluate the safety and efficacy of oral paricalcitol, 220 CKD stage 3 and 4 patients with secondary hyperparathyroidism (SHPT) were randomized to oral paricalcitol (N= 107, mean dose 9.5 microg/week) or placebo (N= 113) and followed for up to 24 weeks. "

11/01/2012 - "This reduction in fibrosis in paricalcitol treated mice was associated with improved indices of LV contraction and relaxation, e.g. "
12/01/2006 - "These studies suggest that paricalcitol is able to ameliorate renal interstitial fibrosis in obstructive nephropathy, possibly by preserving tubular epithelial integrity through suppression of EMT."
09/09/2021 - "The effect of paricalcitol on the HIF-1α-dependent changes of fibrosis markers was not significant after the gene silencing of HIF-1α. "
09/09/2021 - "TGF-β1 increased α-SMA and other fibrosis markers but reduced PDGFRβ expression in pericytes, whereas paricalcitol reversed the changes. "
11/01/2017 - "Both VDRAs attenuated cardiac fibrosis, achieving a statistically significant difference in the paricalcitol-treated group. "

01/01/2013 - "In this study, we investigated the effects of paricalcitol on inflammation and epithelial-mesenchymal transition (EMT) after HHE-induced renal tubular epithelial cell injury. "
01/04/2023 - "In conclusion, paricalcitol exerts a renoprotective effect by decreasing renal oxidative injury and inflammation through Nrf2/HO-1 signaling, providing a new insight into AKI prevention."
07/01/2022 - "The detoxication and anti-inflammation effects of paricalcitol on PM2.5 in vitro were analyzed by LIF, MTT, western blot (WB), ELISA and flow cytometry (FCM). "
01/01/2020 - "Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients."
01/01/2020 - "In a preclinical model of kidney injury, paricalcitol inhibited renal NF-κB2 activation and decreased renal inflammation. "

01/01/2022 - "Paricalcitol was the cause of hypercalcemia in 1.9% of the patients. "
12/01/2018 - "Paricalcitol was well tolerated but incidence of mild hypercalcemia was higher than in placebo. "
10/01/2018 - "The highest dose of paricalcitol administered was 10.5 µg/kg. Hypercalcemia was infrequent and mild in severity. "
09/01/2018 - "Paricalcitol reduces the risk of cardiovascular events in CKD patients but increases the risk of hypercalcemia and cannot improve cardiac structure. "
09/01/2018 - "Compared to placebo, paricalcitol reduced the risk of cardiovascular events (RR 0.55; 95% CI 0.35-0.87; p = 0.01), but the RR of hypercalcemia associated with paricalcitol was 6.50 (95% CI 3.21-13.15; p < 0.00001). "

01/01/2013 - "Paricalcitol is effective in lowering PTH in patients with CKD not yet on dialysis and is also effective in lowering proteinuria in diabetic CKD patients. "
06/09/2017 - "In fact, some studies have shown the beneficial effects of paricalcitol on proteinuria. "
01/01/2013 - "Our study shows an important reduction in proteinuria with a low dose of oral paricalcitol in CKD, that is particularly robust with baseline proteinuria between 1-3 g/d."
10/01/2009 - "Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial."
01/01/2022 - "Antiproteinuric effect of paricalcitol in kidney transplant recipients with severe proteinuria: a prospective cohort study."